文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

SABATO试验方案更新:低风险金黄色葡萄球菌血流感染早期口服转换治疗

Protocol update for the SABATO trial: a randomized controlled trial to assess early oral switch therapy in low-risk Staphylococcus aureus bloodstream infection.
PubMed 文献 · Trials · 2020-02-12

SABATO是一项随机、平行组、非劣效性临床试验,旨在评估低风险金黄色葡萄球菌感染早期口服转换治疗的有效性和安全性。本方案更新描述了最终修订:细化入排标准使特定合并症及未感染异物患者符合条件、采用10%非劣效界值并将中期分析(215例)转为最终分析以降低目标样本量、增加30天随访访视。修订旨在改善患者入组和随访并促进试验完成。

要点

  • 细化入排标准,特定合并症及未感染异物患者可有条件入组。
  • 采用10%非劣效界值,中期分析(215例)转为最终分析以降低样本量。
  • 增加30天随访访视以加强患者随访。

核心结论

  • 方案修订旨在改善患者入组和随访,降低样本量有助于试验完成。

研究设计与样本

  • SABATO为随机、平行组、临床非劣效性试验,评估低风险金黄色葡萄球菌感染早期口服转换治疗的有效性和安全性。
  • 原始试验方案已发表于Trials(https://doi.org/10.1186/s13063-015-0973-x)。

主要发现

  • 共引入三项主要方案修订:细化入排标准、降低目标样本量、增加30天随访访视。

关键数值与推荐

  • 采用常规10%非劣效界值,并将中期分析(215例患者)转为最终分析以降低目标样本量。
  • 细化入排标准后,终末期肾病、严重肝病及未感染异物(骨科假体、起搏器、植入式心律转复除颤器)患者在一定条件下可入组。
  • 增加30天后的额外随访访视。

临床怎么用

  • 为低风险金黄色葡萄球菌血流感染早期口服转换治疗的临床决策提供非劣效性试验证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: SABATO (Staphylococcus aureus bacteremia antibiotic treatment options) is a randomized, parallel-group, clinical non-inferiority trial designed to examine the efficacy and safety of early oral switch therapy in low-risk Staphylococcus aureus infection. The original trial protocol was published in Trials (accessible at https://doi.org/10.1186/s13063-015-0973-x ). Here we describe final amendments to the study protocol and discuss the underlying rationale. METHODS/DESIGN: Three major changes were introduced into the study protocol: (1) the inclusion and exclusion criteria were refined so that patients with certain comorbidities (end-stage renal disease, severe liver disease) and uninfected foreign bodies (orthopedic prosthesis, pacemaker, implanted cardiac cardioverter-defibrillator) became eligible for enrollment under certain conditions; (2) the target sample size was decreased by choosing a conventional non-inferiority margin of 10% and converting the interim analysis (215 patients) into the final analysis; and (3) an additional follow-up visit after 30 days was introduced to allow for a closer follow-up of patients. CONCLUSION: Changes to the study protocol were introduced to improve the enrollment and follow-up of patients. Furthermore, the decrease of the sample size will facilitate completion of the trial. TRIAL REGISTRATION: ClinicalTrials.gov, NCT01792804. Registered on 13 February 2013. German Clinical trials register, DRKS00004741. Registered on 4 October 2013, EudraCT 2013-000577-77.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Kaasch AJ, Rommerskirchen A, Hellmich M, et al. Protocol update for the SABATO trial: a randomized controlled trial to assess early oral switch therapy in low-risk Staphylococcus aureus bloodstream infection. Trials. 2020. PMID: 32051007. doi:10.1186/s13063-020-4102-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。